Investing, Markets & Money

The Armchair Trader

The Armchair Trader Editor, Stuart Fieldhouse calls on his wealth of experience within the financial markets and extensive network of connections to bring you this investing podcast. Stuart invites guests on to the show each week to discuss important themes within the financial markets. His guests include CEO’s of listed companies from around the world, from micro cap stocks to large established businesses. He speaks with Fund Managers about stock picking and the markets in which they operate, and he chats with Market Analysts about a range of topics that offer a broader view of the markets as well as insight on topical themes and trends. Listen on SoundCloud, YouTube or wherever you get your podcasts.

  1. Jul 15

    Gold and rare earths: Bold Ventures expands exploration success in Canada

    In this episode of the Investing, Markets & Money podcast from The Armchair Trader, we welcome back Bruce MacLachlan, President of Bold Ventures, to discuss the company's latest exploration successes across its Canadian mining projects. We explore the recent visible gold discovery at the Traxxin Gold Project, where high-grade drilling results have increased confidence in the project's exploration potential. Bruce explains why the latest findings could significantly expand the known gold mineralisation and what investors should watch for as follow-up drilling gets underway. The conversation also covers Bold Ventures' unexpected rare earth elements discovery at the Burchell Project. With encouraging indications of heavy rare earth mineralisation, alongside existing gold, copper and zinc targets, the project is developing into an exciting critical minerals opportunity at a time when demand for strategic resources continues to rise. We also discuss: - The latest developments at the Joutel and Willcorp projects - Bold Ventures' new OTC listing (BVLDF) for US investors - The outlook for exploration across Ontario and Québec - Why critical minerals and gold remain key themes for investors If you're interested in gold stocks, rare earth elements, critical minerals, Canadian mining stocks and junior mining companies, this episode provides valuable insight into one of Canada's most active explorers. 🎧 Subscribe to the Investing, Markets & Money podcast for more exclusive interviews with CEOs, fund managers and market experts. Visit The Armchair Trader for more investing news, market analysis and exclusive podcast interviews: https://www.thearmchairtrader.com 00:00 Introduction to Bold Ventures 01:11 Exciting Gold Intersections at the Traxxin Project 04:14 Planning the next phase of exploration 06:30 Unexpected Rare Earth Discovery: A Game Changer 11:19 Burchell project strategy 12:34 Joutel project update 14:56 Bold's OTC listing in the US 15:55 Results from Wilcorp project

    Gold and rare earths: Bold Ventures expands exploration success in Canada
  2. Jul 7

    Is This the Most Undervalued Gold Stock in Canada? | Horne Five Explained | Ep.167

    Falco Resources CEO Luc Lessard joins Stuart on this episode of the Investing, Markets & Money podcast to break down the Horne Five project in Quebec - a large-scale, multi-metal deposit the market has yet to fully price in. With an updated feasibility study just released, a 28% IRR, and industry-leading production costs, Luc explains why this could be one of the most overlooked gold stories in Canada. Stay tuned to learn about: ✔️Why the market hasn't priced in the project yet, despite sub-$800/oz production costs (vs. ~$1,400/oz industry average) ✔️Why Horne Five could make Falco a takeover target for a major producer within the next 4–5 years ✔️The updated feasibility study numbers: $3.4B NPV, 28% IRR, built on a $3,600/oz gold price You can find out more about Falco Resources here - https://www.falcores.com/en/ You can sign up to The Armchair Trader free newsletter here - https://www.thearmchairtrader.com/newsletter/ Follow us: BlueSky - https://bsky.app/profile/thearmchairtrader.com Linkedin - https://www.linkedin.com/company/10429893 Instagram - https://www.instagram.com/armchairtrader Facebook - https://www.facebook.com/TheArmchairTrader 01:26 Falco Resources Horne Five project 03:20 Quebec regulatory process 05:07 Latest feasibility study 07:04 The scale of the Horne Five project 07:45 Falco Resources share price 09:37 Financing the project 10:48 How does Horne Five stack up against other projects? 13:54 Project infrastructure 15:26 Why is Horne Five attractive? 19:03 What next for Falco Resources?

    Is This the Most Undervalued Gold Stock in Canada? | Horne Five Explained | Ep.167
  3. May 28

    Biotech Investing in 2026: M&A Boom, FDA Shakeup & the Cancer Drug That Could Double Survival Rates | Ep.163

    Is biotech finally back? In this episode, Stuart sits down with Ailsa Craig, co-manager of the International Biotechnology Trust from Schroders, a £1bn+ closed-ended fund with a 4% dividend yield and 30+ years of history, to break down everything self-directed investors need to know about the biotech sector right now. They cover: ✅ Why biotech has been in a prolonged bear market (and why that's changing) ✅ The M&A wave sweeping the sector — and how IBT is benefiting ✅ FDA uncertainty under the new US administration ✅ AI's real (and realistic) impact on drug development timelines ✅ The pancreatic cancer breakthrough that could be approved within months ✅ Where the best risk-adjusted opportunities are in biotech today ✅ What could be the "next game-changing" moment for the sector? Whether you're new to biotech investing or a seasoned investor looking for smarter sector exposure, this episode gives you a fund manager's inside view on one of the most complex - and rewarding - corners of the market. 🔔 Subscribe for more investing insights every week 👍 Like if you found this useful 💬 Drop your biotech related questions and comments below LINKS & RESOURCES: 🔗 International Biotechnology Trust: https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/ 🎙️ The Armchair Trader: https://www.thearmchairtrader.com DISCLAIMER: This podcast is for informational and educational purposes only and does not constitute financial advice. Always do your own research before making investment decisions. 00:00 Introduction & welcome to Ailsa Craig 00:40 What is the International Biotechnology Trust? 02:28 How biotech boomed - and crashed - after COVID 05:35 Why the FDA matters so much to biotech investors 06:42 Innovation, ageing populations & unmet medical need 08:05 AI in drug development: hype vs. reality 10:06 Biotech strategies for investors 12:04 The "Biotech 2.0" opportunity: de-risked, commercial-stage companies 13:55 A wave of M&A activity this year 16:10 The pancreatic cancer breakthrough changing everything 18:55 What could be biotech's next game-changing moment?

    Biotech Investing in 2026: M&A Boom, FDA Shakeup & the Cancer Drug That Could Double Survival Rates | Ep.163

About

The Armchair Trader Editor, Stuart Fieldhouse calls on his wealth of experience within the financial markets and extensive network of connections to bring you this investing podcast. Stuart invites guests on to the show each week to discuss important themes within the financial markets. His guests include CEO’s of listed companies from around the world, from micro cap stocks to large established businesses. He speaks with Fund Managers about stock picking and the markets in which they operate, and he chats with Market Analysts about a range of topics that offer a broader view of the markets as well as insight on topical themes and trends. Listen on SoundCloud, YouTube or wherever you get your podcasts.

You Might Also Like